Karo Pharma AB (KARO):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Karo Pharma AB (KARO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10031
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:53
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Karo Pharma AB (Karo Pharma), formerly Karo Bio AB, is a health care company that focuses on research and development of pharmaceutical products in the areas of cancer and autoimmune diseases. Its key research area involves nuclear receptors as target proteins for the development of new pharmaceuticals. Karo Pharma discovers drugs to target major diseases including autoimmune diseases such as multiple sclerosis; and multiple types of cancer, viral and bacterial infections. The company’s projects are based on ROR gamma receptor and estrogen receptor. Its development pipeline also includes T268A Cold Spray which utilizes glucose oxidase enzyme in combination with glucose to fight against cold virus. Karo Pharma is headquartered in Huddinge, Stockholm, Sweden.

Karo Pharma AB (KARO) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Karo Pharma AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Karo Pharma AB, Medical Devices Deals, 2012 to YTD 2018 10
Karo Pharma AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Karo Pharma AB, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Karo Pharma Acquires Product Portfolio of Ten Products from LEO Pharma for USD317.6 Million 12
Private Equity 14
EQT VIII to Acquire Karo Pharma for USD652.6 Million 14
Partnerships 15
Karo Bio Enters Into Research Agreement With 4D Science 15
Licensing Agreements 16
Karo Pharma Enters into Licensing Agreement with Marinomed Biotech 16
Weifa Enters into Licensing Agreement with AFT Pharma 17
Karo Bio Enters into Licensing Agreement with Pelago Bioscience for CETSA 18
Equity Offering 19
Karo Pharma Raises USD151.5 Million in Rights Offering of Shares 19
Karo Bio to Raise USD29.7 Million in Rights Offering of Preferred Shares 20
Weifa Raises USD13.6 Million in Private Placement of Shares 21
Karo Bio Raises USD29 Million in Rights Offering of Shares 22
Aqualis to Raise USD116.7 Million in Private Placement of Shares 23
Aqualis to Raise USD16.7 Million in Rights Offering of Shares 24
Karo Bio Raises USD12 Million in Rights Offering of Shares 25
Karo Bio Raises USD1 Million in Private Placement of Shares 26
Aqualis Completes Private Placement Of Shares For US$4 Million 27
Aqualis Completes Private Placement Of Shares For US$4.7 Million 28
Aqualis Completes Rights Offering Of Shares For US$9 Million 29
Karo Bio Completes Rights Offering of Shares for USD4.9 Million 30
Debt Offering 31
Aqualis to Raise USD66.7 Million in Public Offering of Bonds 31
Asset Transactions 32
Oasmia Pharma Acquires Cancer Project KB9520 from Karo Pharma 32
Acquisition 33
Karo Pharma Acquires Weifa 33
Karo Pharma Acquires 100% Stake in Medireduce 35
Karo Pharma Acquires BioPhausia from Medivir for USD95 Million 36
Karo Bio Acquires Tanomed for USD2.3 Million 37
Aqualis Completes Acquisition of Weifa for USD183.6 Million 38
Karo Pharma AB – Key Competitors 39
Karo Pharma AB – Key Employees 40
Karo Pharma AB – Locations And Subsidiaries 41
Head Office 41
Other Locations & Subsidiaries 41
Recent Developments 42
Financial Announcements 42
Jul 19, 2018: Karo pharma triples sales and profit in the second quarter 42
Apr 26, 2018: Karo Pharma Doubles Sales and Earnings in the First Quarter 44
Feb 22, 2018: Karo Pharma: Year-end Report 2017 45
Nov 02, 2017: Karo Pharma: Interim Report January– September 2017 46
Aug 24, 2017: Karo Pharma: Interim Report January–June 2017 48
May 10, 2017: Karo Pharma: interim report January – March-2017 49
Feb 28, 2017: Karo Pharma: Full Year Report 2016 50
Corporate Communications 51
Mar 23, 2018: Karo Pharma Supports Operation Smile 51
Product News 52
05/21/2018: UTILITY Therapeutics Receives Qualified Infectious Disease Product Designation from the U.S. FDA for Mecillinam 52
Appendix 53
Methodology 53
About GlobalData 53
Contact Us 53
Disclaimer 53

List of Tables
Karo Pharma AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Karo Pharma AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Karo Pharma AB, Deals By Therapy Area, 2012 to YTD 2018 9
Karo Pharma AB, Medical Devices Deals, 2012 to YTD 2018 10
Karo Pharma AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Karo Pharma Acquires Product Portfolio of Ten Products from LEO Pharma for USD317.6 Million 12
EQT VIII to Acquire Karo Pharma for USD652.6 Million 14
Karo Bio Enters Into Research Agreement With 4D Science 15
Karo Pharma Enters into Licensing Agreement with Marinomed Biotech 16
Weifa Enters into Licensing Agreement with AFT Pharma 17
Karo Bio Enters into Licensing Agreement with Pelago Bioscience for CETSA 18
Karo Pharma Raises USD151.5 Million in Rights Offering of Shares 19
Karo Bio to Raise USD29.7 Million in Rights Offering of Preferred Shares 20
Weifa Raises USD13.6 Million in Private Placement of Shares 21
Karo Bio Raises USD29 Million in Rights Offering of Shares 22
Aqualis to Raise USD116.7 Million in Private Placement of Shares 23
Aqualis to Raise USD16.7 Million in Rights Offering of Shares 24
Karo Bio Raises USD12 Million in Rights Offering of Shares 25
Karo Bio Raises USD1 Million in Private Placement of Shares 26
Aqualis Completes Private Placement Of Shares For US$4 Million 27
Aqualis Completes Private Placement Of Shares For US$4.7 Million 28
Aqualis Completes Rights Offering Of Shares For US$9 Million 29
Karo Bio Completes Rights Offering of Shares for USD4.9 Million 30
Aqualis to Raise USD66.7 Million in Public Offering of Bonds 31
Oasmia Pharma Acquires Cancer Project KB9520 from Karo Pharma 32
Karo Pharma Acquires Weifa 33
Karo Pharma Acquires 100% Stake in Medireduce 35
Karo Pharma Acquires BioPhausia from Medivir for USD95 Million 36
Karo Bio Acquires Tanomed for USD2.3 Million 37
Aqualis Completes Acquisition of Weifa for USD183.6 Million 38
Karo Pharma AB, Key Competitors 39
Karo Pharma AB, Key Employees 40
Karo Pharma AB, Subsidiaries 41

List of Figures
Karo Pharma AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Karo Pharma AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Karo Pharma AB, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Karo Pharma AB (KARO):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Ascendance Biotechnology Inc-製薬・医療分野:企業M&A・提携分析
    Summary Ascendance Biotechnology Inc (Ascendance), formerly Hepregen Corp is a healthcare products provider that offers cell based assay products. The company provides vitro micro-liver cell-based platforms for use in safety testing, and pharmaceutical, biotherapeutic and diagnostic product developm …
  • Strongbridge Biopharma plc (SBBP):企業の財務・戦略的SWOT分析
    Summary Strongbridge Biopharma plc (Strongbridge) formerly Cortendo Plc, is a commercial-stage biopharmaceutical company that develops and commercializes therapies for rare diseases. The company’s marketed product KEVEYIS (dichlorphenamide) is indicated for the treatment of hypokalemic, hyperkalemic …
  • The J.M. Smucker Co:企業の戦略・SWOT・財務情報
    The J.M. Smucker Co - Strategy, SWOT and Corporate Finance Report Summary The J.M. Smucker Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Colonial Penn Life Insurance Company:企業の戦略・SWOT・財務情報
    Colonial Penn Life Insurance Company - Strategy, SWOT and Corporate Finance Report Summary Colonial Penn Life Insurance Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Orsted Salg & Service AS:企業の戦略的SWOT分析
    Orsted Salg & Service AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Seair Inc:企業の戦略的SWOT分析
    Seair Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • Doosan Infracore Co Ltd (042670):企業の財務・戦略的SWOT分析
    Doosan Infracore Co Ltd (042670) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • PharmaCyte Biotech Inc (PMCB):製薬・医療:M&Aディール及び事業提携情報
    Summary PharmaCyte Biotech Inc (PharmaCyte), formerly Nuvilex Inc, is a clinical stage biotechnology company that develops and commercializes treatments for cancer and diabetes. The company offers technology is used for the treatment of advanced and inoperable pancreatic cancer and diabetes. It deve …
  • Banco Bilbao Vizcaya Argentaria Colombia SA:企業の戦略・SWOT・財務分析
    Banco Bilbao Vizcaya Argentaria Colombia SA - Strategy, SWOT and Corporate Finance Report Summary Banco Bilbao Vizcaya Argentaria Colombia SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation …
  • Sonoma Orthopedic Products Inc-医療機器分野:企業M&A・提携分析
    Summary Sonoma Orthopedic Products Inc (Sonoma) is a medical device company that offers orthopedic products. The company provides long bone fixation system that reduces fixation time and patient discomfort. Its product include ankle pin, collarbone pin and wrist pin. Sonoma provides treatment for wr …
  • Schneider Electric SE:企業の戦略・SWOT・財務分析
    Schneider Electric SE - Strategy, SWOT and Corporate Finance Report Summary Schneider Electric SE - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Okinawa Electric Power Company Incorporated (9511):企業の財務・戦略的SWOT分析
    Okinawa Electric Power Company Incorporated (9511) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key …
  • PAR Technology Corp (PAR):企業の財務・戦略的SWOT分析
    Summary PAR Technology Corp (PAR) is a technology company that offers systems and solutions for the hospitality industry. The company offers services such as project management, education services, deployment services, on-site field services, depot repair, and managed services. It also implements fo …
  • Mediolanum farmaceutici SpA:製薬・医療:M&Aディール及び事業提携情報
    Summary Mediolanum farmaceutici SpA (Mediolanum) is a developer and supplier of pharmaceuticals products and prescription drugs. The company offers products in therapeutic areas, which include neuropsychiatric, osteoarticular, antibiotic, pneumoallergological, vascular area and cardiometabolics. It …
  • Central Electricity Generating Co:企業の戦略的SWOT分析
    Central Electricity Generating Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • Vital Therapies Inc (VTL):医療機器:M&Aディール及び事業提携情報
    Summary Vital Therapies Inc (Vital Therapies) is a biotechnology company that discovers, develops and commercialize cell-based therapies. The company’s product candidate includes ELAD system, a human-cell-based bio artificial liver treatment designed to allow the patient's own liver to regenerate or …
  • Laboratory Corporation of America Holdings:企業のM&A・事業提携・投資動向
    Laboratory Corporation of America Holdings - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Laboratory Corporation of America Holdings Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detai …
  • Immuron Ltd (IMC):企業の財務・戦略的SWOT分析
    Summary Immuron Ltd (Immuron), formerly Anadis Ltd is a biopharmaceutical company that develops oral immunotherapy therapeutics using polyclonal antibody products for humans. The company develops and produces an orally stable therapeutic for various immune mediated and inflammatory disorders. It pro …
  • Jardine Matheson Holdings Ltd:企業の戦略・SWOT・財務分析
    Jardine Matheson Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Jardine Matheson Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Twenty-First Century Fox Inc. (FOXA):企業の財務・戦略的SWOT分析
    Twenty-First Century Fox Inc. (FOXA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆